目的 探討肝爽顆粒聯(lián)合聚乙二醇干擾素α-2a治療慢性乙型肝炎的臨床效果。方法 選取2016年1月-2016年9月在寶雞市中醫(yī)醫(yī)院接受治療的84例慢性乙型肝炎患者為研究對象，根據(jù)治療方案的差別分為對照組（42例）和治療組（42例）。對照組患者皮下注射聚乙二醇干擾素α-2a注射液0.5 mL，1次/周。治療組患者在對照組的基礎(chǔ)上口服肝爽顆粒，3 g/次，3次/d。兩組患者均治療3個月。評價兩組患者臨床療效，同時比較治療前后兩組患者肝功能以及血清白介素-17 （IL-17）、巨噬細(xì)胞移動抑制因子（MIF）和HBV-DNA水平。結(jié)果 治療后，對照組和治療組總有效率分別為80.95%、95.24%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清肝功能丙氨酸氨基轉(zhuǎn)移酶（ALT）、門冬氨酸轉(zhuǎn)氨酶（AST）、總膽紅素（TBIL）水平以及IL-17、MIF和HBV-DNA水平均顯著降低，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者上述觀察指標(biāo)顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 肝爽顆粒聯(lián)合聚乙二醇干擾素α-2a治療慢性乙型肝炎可有效改善機(jī)體肝功能和血清IL-17、MIF和HBV-DNA水平，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Ganshuang Granules combined with peginterferon α-2a in treatment of chronic hepatitis B. Methods Patients (84 cases) with chronic hepatitis B in Baoji City Hospital of TCM from January 2016 to September 2016 were divided into control (42 cases) and treatment (42 cases) groups according to different treatments. Patients in the control group were subcutaneous injection administered with Peginterferon α-2a Solution for injection, 0.5 mL/time, once weekly. Patients in the treatment group were po administered with Ganshuang Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the liver function, serum IL-17, MIF, and HBV-DNA level in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.95% and 95.24%, respectively, and there were differences between two groups (P<0.05). After treatment, the ALT, AST, TBIL, IL-17, MIF and HBV-DNA level in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these observation indexes in the treatment group were obviously lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ganshuang Granules combined with peginterferon α-2a can significantly improve the liver function and serum IL-17, MIF and HBV-DNA level in treatment of chronic hepatitis B, which has a certain clinical application value.